Browse RMI1

Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Forms foci in response to DNA damage.
Domain PF16099 Recq-mediated genome instability protein 1
PF08585 RecQ mediated genome instability protein
Function

Essential component of the RMI complex, a complex that plays an important role in the processing of homologous recombination intermediates to limit DNA crossover formation in cells. Promotes TOP3A binding to double Holliday junctions (DHJ) and hence stimulates TOP3A-mediated dissolution. Required for BLM phosphorylation during mitosis. Within the BLM complex, required for BLM and TOP3A stability.

> Gene Ontology
 
Biological Process GO:0000731 DNA synthesis involved in DNA repair
GO:0000732 strand displacement
GO:0002021 response to dietary excess
GO:0002023 reduction of food intake in response to dietary excess
GO:0006260 DNA replication
GO:0006310 DNA recombination
GO:0007631 feeding behavior
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009991 response to extracellular stimulus
GO:0031667 response to nutrient levels
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0035264 multicellular organism growth
GO:0042593 glucose homeostasis
GO:0042755 eating behavior
GO:0071897 DNA biosynthetic process
GO:0072331 signal transduction by p53 class mediator
GO:1901796 regulation of signal transduction by p53 class mediator
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa03460 Fanconi anemia pathway
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-69481: G2/M Checkpoints
R-HSA-69473: G2/M DNA damage checkpoint
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5685942: HDR through Homologous Recombination (HRR)
R-HSA-5685938: HDR through Single Strand Annealing (SSA)
R-HSA-5693579: Homologous DNA Pairing and Strand Exchange
R-HSA-5693538: Homology Directed Repair
R-HSA-5693616: Presynaptic phase of homologous DNA pairing and strand exchange
R-HSA-5693607: Processing of DNA double-strand break ends
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-5693537: Resolution of D-Loop Structures
R-HSA-5693568: Resolution of D-loop Structures through Holliday Junction Intermediates
R-HSA-5693554: Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RMI1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RMI1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RMI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2090.422
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2120.813
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2130.78
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0760.864
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.250.835
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1370.933
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0580.831
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0860.94
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2750.82
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1050.881
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6560.499
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3967.82e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RMI1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RMI1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RMI1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RMI1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RMI1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RMI1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RMI1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRMI1
NameRecQ mediated genome instability 1
Aliases FLJ12888; BLAP75; BLM-Associated Polypeptide, 75 kDa; C9orf76; chromosome 9 open reading frame 76; RMI1, Rec ......
Chromosomal Location9q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RMI1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.